BioAtla Inc
BioAtla Inc (BCAB) is a clinical-stage biotechnology company focused on developing conditionally active biologic (CAB) therapies, primarily for oncology. The CAB platform aims to activate antibodies selectively in the tumour microenvironment, potentially improving efficacy while reducing systemic side effects. For investors, key considerations include the early-stage nature of the pipeline, reliance on clinical trial results and regulatory milestones, and a small market capitalisation (around $40.5M) which can mean heightened share-price volatility and financing risk. Catalysts that could move the stock include trial readouts, data updates, partnership deals and financing announcements. Conversely, setbacks in studies or the need to raise capital could dilute shareholders and pressure the share price. This profile is educational and not investment advice; clinical outcomes are uncertain and past performance does not predict future returns. Investors should assess their risk tolerance, review company filings, and consider seeking independent financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying BioAtla's stock, predicting it could reach $8.5 soon.
Financial Health
BioAtla Inc is producing a modest amount of cash flow per share, indicating steady operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BCAB
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
CAB technology focus
The company’s conditionally active biologics aim to work selectively in tumours; potential benefits exist, but clinical proof is required and outcomes can vary.
Binary clinical catalysts
Trial readouts and regulatory updates can drive meaningful share moves; this creates opportunity but also sharp downside risk if results disappoint.
Partnerships & funding
Collaborations or licensing deals could validate the platform and provide funding, while capital raises may dilute existing holders—assess runway carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
